Compare AIN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | NVCR |
|---|---|---|
| Founded | 1895 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Textiles | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1994 | 2015 |
| Metric | AIN | NVCR |
|---|---|---|
| Price | $56.82 | $10.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $60.25 | $28.08 |
| AVG Volume (30 Days) | 229.2K | ★ 1.0M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,054,132,000.00 | $655,353,000.00 |
| Revenue This Year | $1.20 | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.29 | ★ 8.28 |
| 52 Week Low | $41.15 | $9.82 |
| 52 Week High | $73.00 | $20.05 |
| Indicator | AIN | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.71 | 42.85 |
| Support Level | $54.15 | N/A |
| Resistance Level | $60.43 | $13.59 |
| Average True Range (ATR) | 1.67 | 0.55 |
| MACD | 0.64 | -0.06 |
| Stochastic Oscillator | 96.34 | 33.49 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.